FOR SUCCESS YOUR PRESCRIPTION SPEAK. Business

Transcription

1 YOUR PRESCRIPTION FOR SUCCESS Georgia is on the pulse of bioscience. After all, the industry has a $7.5 billion impact on our GDP and employs more than 70,000 people in our state. Find out why 300-plus bioscience companies call us home. Let s talk about a healthy future for your company in Georgia. We SPEAK Business Visit Georgia.org to find out how you can become our state s next success story.

2 Healthy finish, healthy start $258 million Follow-On Offering Option to Acquire up to $165 million Acquisition of Co-Manager December 2011 Financial Advisor December 2011 Exclusive Financial Advisor November 2011 $54 million Initial Public Offering $50 million Follow-On Offering ZyStor Therapeutics, Inc. $115 million* Sale to BioMarin Pharmaceutical, Inc. Co-Manager April 2011 Co-Manager January 2011 Financial Advisor August 2010 Last year, BMO Capital Markets led 465 capital raising and M&A transactions totaling $160 billion. Let us help you achieve your ambitions for a strong BMO Capital Markets is a trade name used by BMO Financial Group for the wholesale banking businesses of Bank of Montreal, BMO Harris Bank N.A. and Bank of Montreal Ireland p.l.c., and the institutional broker dealerbusinesses of BMO Capital Markets Corp., BMO Nesbitt Burns Trading Corp. S.A., BMO Nesbitt Burns Securities Limited and BMO Capital Markets GKST Inc. in the U.S., BMO Nesbitt Burns Inc. in Canada, Europe and Asia, BMONesbitt Burns Ltée/Ltd. in Canada, BMO Capital Markets Limited in Europe, Asia and Australia and BMO Advisors Private Limited in India. Registered trademark of Bank of Montreal in the United States, Canada and elsewhere. * Upfront and potential milestone payments.

3 Your Partners for Pharmaceutical Strategy and Innovation Catenion is a management consulting firm devoted to helping pharmaceutical and medical products companies significantly increase the returns on their R & D and marketing investments by creating more innovative and effective strategies and organizations.

4 A partnership specializing in drug royalty acquisitions and structured financings for commercial-stage healthcare products and companies with over $1.5 billion under management. Licensing & Funded Research Program Dyax Corp. Biosense Webster Catheters Johnson & Johnson Galderma/Allergan AcuFocus University Inventor $80 Million $20 Million Undisclosed $30 Million Undisclosed december 2011 december 2011 november 2011 november 2011 november 2011 University Inventor University Inventor Zogenix Undisclosed European Pharma Co. Project Financing Astellas Pharma Merck Serono Undisclosed Undisclosed $33 Million $84 Million $40 Million $55 Million november 2011 november 2010 April 2010 november 2008 Licensing & Funded Research Program/ Galderma/Allergan Santarus Inc. Dyax Allergan GlaxoSmithKline Suneva Medical $23 Million $29 Million $70 Million $25 Million $61 Million Undisclosed october 2008 september 2008 August 2008 August 2008 may 2008 JAnuAry 2008 Founding MAnAging directors: gregory B. Brown, M.d. todd c. davis clarke B. Futch Broad Street, Suite 1101 Stamford, Ct 06901

5 A full-service investment banking firm serving the emerging growth sectors in healthcare, biotech and technology. S E L E C T T R A N S A C T I O N S: Joseph Balagot Managing Partner/Head of Investment Banking Telephone: jbalagot@dawsonjames.com Boca Raton, FL San Francisco, CA New York, NY Member FINRA/SIPC Member FINRA/SIPC The above communication is intended for informational purposes only and is not to be interpreted by the recipient as a solicitation to participate in securities offerings. The Company may have prior, existing or proposed investment banking relationships with referenced entities and may engage in trading the securities on an agency or principal basis. The Company, its officers, directors analysts or employees may effect transactions, or hold long or short positions, in the securities referenced or their related components or entities.

6 FORWARD THINKING GSK s unique R&D organization has successfully worked with a diverse range of collaboration types and is absolutely committed to furthering our R&D efforts through externalization in pursuit of the best science. GSK collaborations include: Option based collaborations We believe these unique business models truly nurture innovation. For option based collaborations, we seek out organizations that have a robust discovery engine and the capability of developing compounds to clinical proof of concept, at which point GSK would have an option for further development and commercialization. Late stage licensing Over the past eight years, GSK signed more late stage collaborations than anyone else in the industry. In fact, a large portion of our current late stage pipeline comes from these collaborations. Acquisitions We have completed a number of acquisitions over the past 4 years, and we believe in keeping the innovative spirit as part of our approach to acquisitions. GlaxoSmithKline Worldwide Business Development 709 Swedeland Road King of Prussia, PA ww.bd@gsk.com

7 is a proud sponsor of the BIO CEO & Investor Conference. Contacts: Mark Schoenebaum, MD ISI Group Biotech & Pharmaceuticals Analyst cell mschoenebaum@isigrp.com AIM: markschoenebaum Catherine P. Miles ISI Group Head of Corporate Access cell cmiles@isigrp.com AIM: cmilesisi 40 West 57th Street New York, NY

8

9 ... Leerink - sponsor banking ad_rd3a Focus on Healthcare. Focus on Investment Banking. Focus on Clients. These are the guiding principles at Leerink Swann that set us apart as the most knowledgeable healthcare investment bank. Our clients share our belief that successfully capitalizing on healthcare opportunities requires a deep understanding of this complex and ever-changing industry. The result is that our clients trust that they are making sound decisions, guided by a partner that shares an interest in their success. Copyright 2011, Leerink Swann LLC. All rights reserved. This is not an offer or solicitation to purchase securities, which can only be done via prospectus. Leerink Swann is a trademark of Leerink Swann LLC. Member FINRA and SIPC.

10 TM Knowledge Captured & Delivered SM MedPanel specializes in providing medical market insights to help biopharma companies commercialize and license out their drugs. Whether you need reliable market data to make informed product development decisions or to fuel a credible forecast for partnering discussions, MedPanel is the research partner on which you can rely. To learn more about the value MedPanel can add to help ensure your commercial success, please contact us. Contact: Howard Brick, CEO MedPanel, LLC 150 Cambridge Park Drive Cambridge, MA Howard.brick@medpanel.com

11 Copyright 2012 Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc. All rights reserved. Merck is known as MSD outside the United States and Canada. Combining Our Strengths Sharing Our Successes Partnering with Merck helps us to succeed. a biotech company innovative therapeutic approach We are with an to treat patients with Alzheimer, s Disease. important validation of our science synergy of our collaboration accelerate our development timeline Our partnership with Merck is an and the is helping us. Ernest McEachern Alectos Therapeutics successfully advance our program I m from and Merck is helping us to. Merck seeks partnerships across many therapeutic areas and technologies. Learn more at merck.com /licensing

12 Paul Capital Healthcare is pleased to support the 2012 BIO CEO & Investor Conference New York John R. Leone 140 E. 45th Street 44th Floor New York, NY (646) London Ken Macleod, PhD 22 Sackville Street 4th Floor London, W1S 3DN 44 (20)

13 Rodman & Renshaw, LLC A Full Service Investment Bank We are dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions Rodman & Renshaw, LLC Member FINRA, SIPC I N ves t M e N t BANk INg S ALe S & trad INg e QUIt Y ReS e ARCh

14 ///////////////////////////////////////////////////////////////////////////////////////////////////////////////// Recent Healthcare Transactions Since 2010, ROTH has raised over $1.7 billion in over 85 healthcare transactions $11,000,000 $30,800,000 $23,699,000 $150,000,000 $5,830,000 8,421,000 $10,000,000 $3,504,000 $4,000,000 CONVERTIBLE NOTES IPO SOLE BOOK-RUNNER JOINT BOOK-RUNNING MANAGER January 2012 January 2012 January 2012 January 2012 December 2011 December 2011 December 2011 October 2011 October 2011 $25,478,000 $6,940,000 $48,000,000 $20,209,000 $20,400,000 3,200,000 $10,360,000 $7,500,000 $7,000,000 $5,162,000 JOINT BOOK-RUNNING MANAGER PLACEMENT AGENT September 2011 September 2011 $3,000,000 $8,407,000 $4,000,000 $29,000,000 $15,000,000 $4,000,000 $36,225,,000 $9,774,000 $23,000,000 $34,500,000 PLACEMENT AGENT SOLE MANAGER June 2011 June 2011 June 2011 June 2011 June 2011 May 2011 May 2011 May 2011 May 2011 May 2011 $33,000,000 C$12,400,000 $3,000,000 $35,167,000 $13,215,000 $11,950,000 $20,000,000 $15,000,000 $25,100,000 $2,531,000 SOLE MANAGER IPO May 2011 May 2011 April 2011 April 2011 April 2011 April 2011 April 2011 March 2011 March 2011 March 2011 $8,100,000 $23,000,000 $21,800,000 $1,600,000 $5,100,000 $41,113,000 $24,300,000 $82,225,000 $46,000,000 March 2011 March 2011 SOLE MANAGER February 2011 February 2011 February 2011 January 2011 January 2011 January 2011 WARRANT EXCHANGE January 2011 December 2010 $28,750,000 $100,000,000 $22,500,000 $18,000,000 $10,450,000 $7,000,000 $3,303,000 $17,308,000 $5,718,000 JOINT BOOK-RUNNING MANAGER DEBTOR-IN-POSSESSION FINANCING M & A ADVISOR December 2010 December 2010 December 2010 December 2010 November 2010 November 2010 November 2010 November 2010 October 2010 October 2010 $15,200,000 $40,250,000 $14,850,000 $7,070,000 $51,105,000 C$7,500,000 $2,756,000 $3,900,000 $52,438,000 PLACEMENT AGENT PLACEMENT AGENT ATM October 2010 October 2010 September 2010 August 2010 August 2010 August 2010 August 2010 August 2010 July 2010 June 2010 $32,000,000 $100,000,000 12,000,000 $5,000,000 $2,500,000 $9,681,000 $2,500,000 $17,500,000 PRIVATE PLACEMENT SELLING AGENT SALE OF COMPANY CHAPTER 11 LEAD PLACEMENT AGENT June 2010 June 2010 June 2010 May 2010 May 2010 May 2010 April 2010 April 2010 April 2010 March 2010 $7,500,000 $80,500,000 $2,000,000 $20,000,000 $7,763,000 $28,000,000 $24,578,000 $5,875,000 $7,154,000 7,500,000 FOLLOW ON LEAD PLACEMENT AGENT March 2010 March 2010 February 2010 February 2010 February 2010 February 2010 January 2010 January 2010 January 2010 January 2010 As of January 11, 2012 For more information about ROTH's Healthcare Investment Banking, please contact: John W. Chambers, Managing Director, Head of Healthcare, Investment Banking Cell: jchambers@roth.com Lisa Walters-Hoffert, Managing Director, Investment Banking Cell: lwalters@roth.com Michael A. Margolis, R.Ph., Managing Director, Investment Banking Cell: mmargolis@roth.com Headquarters: 888 San Clemente Drive, Newport Beach, CA Offices: Los Angeles, CA New York, NY San Diego, CA Seattle, WA Radnor, PA Shanghai Representative Office, CHINA Hong Kong, CHINA Member SIPC/FINRA

15 VWR Accelerating Life Science Solutions GLOBAL REACH, LOCAL SUPPORT. SINCE VWR is a global leader in the distribution of laboratory products, supplies and services, offering the best product choices, including the Exclusive VWR Collection, from premier manufacturers to customers around the globe. We are committed to providing efficient, effective solutions for all your Life Science needs by offering products, service and support that make your work faster, easier and more accurate.